Ascendis Pharma Management

Management Kriterienprüfungen 2/4

Ascendis Pharma's CEO ist Jan Mikkelsen, ernannt in Dec 2007, hat eine Amtszeit von 16.42 Jahren. besitzt direkt 0.74% der Aktien des Unternehmens, im Wert von R$285.29M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.8 Jahre bzw. 6.3 Jahre.

Wichtige Informationen

Jan Mikkelsen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	16.6yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	7.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Jan Mikkelsen (64 yo)

16.6yrs

Amtszeit

Mr. Jan Moller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. He is Director at Eyconis, Inc. He se...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Mikkelsen	President	16.6yrs	keine Daten	0.74% € 311.8m
Scott Smith	CFO, Executive VP & Member of Executive Board	7.9yrs	keine Daten	0.0070% € 3.0m
Lotte Sonderbjerg	Executive VP	16.6yrs	keine Daten	0.0032% € 1.4m
Michael Jensen	Executive VP	11.1yrs	keine Daten	0.0034% € 1.4m
Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	less than a year	keine Daten	keine Daten
Timothy Lee	Senior Director of Investor Relations	no data	keine Daten	keine Daten
Flemming Jensen	Executive Vice President of Product Supply & Quality	8.9yrs	keine Daten	0.0032% € 1.4m
Kennett Sprogoe	Executive VP and Head of Research & Product Development	8.5yrs	keine Daten	0.0050% € 2.1m
Stina Singel	Executive VP & Head of Clinical Development for Oncology	2.5yrs	keine Daten	keine Daten
Joseph Kelly	Head of U.S. Commercial of Endocrinology	2.2yrs	keine Daten	keine Daten
Scott Holmes	Head of Global Commercial Strategy of Endocrinology	2.2yrs	keine Daten	keine Daten
Camilla Hartvig	Executive VP & Global Chief Commercial Officer	1.1yrs	keine Daten	keine Daten

7.9yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von A1SN34 ist erfahren und erfahren (durchschnittliche Amtszeit: 7.8 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Mikkelsen	President	16.6yrs	keine Daten	0.74% € 311.8m
Albert Cha	Independent Chairman	9.7yrs	€139.72k	0.00068% € 287.3k
William Fairey	Independent Director	1.8yrs	€73.01k	0% € 0
Lisa Morrison	Independent Director	7.3yrs	€92.64k	0.00068% € 287.3k
Lars Holtug	Independent Director	5.7yrs	€96.17k	0.0016% € 659.0k
Siham Imani	Independent Director	1.8yrs	€69.48k	0% € 0

6.5yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrener Vorstand: A1SN34Die Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Ascendis Pharma Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter